PIK3CA and osteosarcoma: In preclinical studies, BYL719 was shown to have anti-tumor activity in many cancer cell types namely nasopharyngeal, head and neck and osteosarcoma cells and recent evidence suggested PIK3CA mutant cells to be more sensitive to BYL719 [26, 45–47].